Lvegun,

I will listen again. I believe he addressed phase 3 in two ways.

The first was that a larger trial would achieve statistical significance in the CD10 primary endpoint (improvement in subjective criteria of myalgia, cough, fever, dyspnea). You are correct that more patients would be a pill.

The second point (I don't believe I misunderstood), was that NEWS2 can be made primary endpoint in a phase 3 and would have statistical significance with trial size in phase 2 CD10 as that is exactly what Cytodyn achieved.

Logically then, Nader said/inferred that there is no need for the phase 3 as the trial they would conduct has essentially already been completed with significant results.

Thanks for the correction.